Jefferies initiated coverage on BeiGene with a new price target
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of BeiGene with a rating of Buy and set a new price target of $287.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/3/2024 | $300.00 | Overweight | Morgan Stanley |
| 9/18/2024 | $288.00 | Mkt Outperform | JMP Securities |
| 2/6/2024 | $185.00 | Overweight | JP Morgan |
| 9/12/2023 | $259.00 | Outperform | Macquarie |
| 8/17/2023 | $287.00 | Buy | Jefferies |
| 7/17/2023 | $275.00 | Buy | Citigroup |
| 6/30/2023 | $335.00 → $196.00 | Outperform → Mkt Perform | Bernstein |
| 1/12/2023 | $308.00 | Buy | Daiwa Securities |